knowledge -WSS

knowledge

author：comprehensive 2025-08-25 05:57:08 - browse：95755

Christoph Lengauer stands for a portrait. -- biotech coverage from STAT — Christoph Lengauer, co-founder and CSO of Curie.Bio Vanessa Leroy for STAT

Curie.Bio, the new biotech investment firm and incubator launched earlier this year by a group of industry veterans including Alexis Borisy and Zach Weinberg, has graduated its first startup.

The startup, Forward Therapeutics, is coming out of the incubator with three drug candidates for chronic inflammatory disorders. It also just closed its first major financing round: a $50 million Series A round led by BVF Partners, with participation from RA Capital Management and OrbiMed. That money should be enough for Forward to begin clinical trials — a rare feat in the biotech world, where companies often need to raise multiple private financing rounds in order to be ready for human tests.

“Usually, with Series A money, you get a development candidate, and use Series B to take molecules to the clinic,” Forward CEO Toufike Kanouni told STAT. But with the Curie team’s help, and the $8 million in seed financing it provided, Forward was able to move much faster.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Change Healthcare can notify patients about the breach, HHS says

WSS

Clinical trials must include more disabled people

Listen: Racing for gene therapy & a pioneering approval

Vaccine critic Robert F. Kennedy Jr. says he'll chair Trump vaccine panel

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

Living with Hashimoto's and celiac disease, and med school, too

ProMED sees offers of support, but its future remains unclear

entertainment

knowledge

hotspot

Anesthesiologist group: stop taking Ozempic before surgery

Living with Hashimoto's and celiac disease, and med school, too

Malaria cases in Florida and Texas: Here’s what you need to know

The boys, now 6, who are gene therapy’s ‘edge case’ problem

Affirmative action in medical school literally saved lives

The Pandemic Treaty must support building strong health systems

Moonlake's readout produced a cash windfall. Risks remain

Ultragenyx gene therapy for rare liver ailment succeeds in late

Medicare proposal to cover medical devices draws a mixed reaction

Trump cancels press conference intended to dispute Georgia election interference charges

entertainment

Listen: Racing for gene therapy & a pioneering approval

Trump cancels press conference intended to dispute Georgia election interference charges

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

Lung cancer is America's deadliest cancer. Yet so few get screened

Special counsel raises new conflict of interest concerns for De Oliveira's lawyer

Innovation in antibiotics is ailing. 'Brain drain' may kill it

entertainment

focus

focus

hotspot